Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
NCT ID: NCT07274787
Last Updated: 2025-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
10 participants
INTERVENTIONAL
2026-01-01
2029-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NCT06329570
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NCT06496971
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NCT04446416
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
NCT01564914
Pembrolizumab +/- Bevacizumab for Recurrent GBM
NCT02337491
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Safety will be assessed using the following methods: Device-related Adverse Events (AEs) reported \[Time Frame: Through study completion, up to 24 weeks\].
To determine the incidence and severity of device-related AEs for bevacizumab plus NaviFUS System treatment in patients with recurrent glioblastoma multiforme (rGBM), the following safety parameters will be assessed: AEs, physical examination (PE), vital signs, neurological examination (NE), Karnofsky Performance Status (KPS), Mini-Mental State Examination (MMSE), clinical laboratory tests, proteinuria, and ECG.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NaviFUS + bevacizumab
NaviFUS system with concomitant microbubble administration in conjunction with bevacizumab (BEV)
NaviFUS System
The NaviFUS System is a FUS phased array system intended to transcranially deliver burst-mode ultrasound energy with the concurrent microbubble intravenous administration to temporally and locally open the BBB. The NaviFUS System is indicated for use to enhance the permeability of conventionally administered therapeutic agents into targeted brain tissue to enhance their therapeutic effects.
Lumason
The NaviFUS System is a FUS phased array system intended to transcranially deliver burst-mode ultrasound energy with the concurrent microbubble intravenous administration to temporally and locally open the BBB.
Bevacizumab
In this proposed clinical investigation, the NaviFUS System will be used in conjunction with BEV in recurrent GBM patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NaviFUS System
The NaviFUS System is a FUS phased array system intended to transcranially deliver burst-mode ultrasound energy with the concurrent microbubble intravenous administration to temporally and locally open the BBB. The NaviFUS System is indicated for use to enhance the permeability of conventionally administered therapeutic agents into targeted brain tissue to enhance their therapeutic effects.
Lumason
The NaviFUS System is a FUS phased array system intended to transcranially deliver burst-mode ultrasound energy with the concurrent microbubble intravenous administration to temporally and locally open the BBB.
Bevacizumab
In this proposed clinical investigation, the NaviFUS System will be used in conjunction with BEV in recurrent GBM patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically confirmed glioblastoma at original diagnosis, recurrent after prior radiotherapy and temozolomide chemotherapy.
3. Must have measurable disease ≥ 10mm (according to RANO criteria) .
4. Interval since completion of radiation treatment (including radiation at original diagnosis and/or radiation for recurrent disease) ≥ 12 weeks.
5. If on steroids, must be on a stable dose for ≥ 7 days prior to study treatment.
6. Body mass index (BMI) ≥17 kg / m2.
7. Minimum interval since last drug therapy:
1. 1 week for non-cytotoxic agents (e.g., interferon, tamoxifen), daily chemotherapy (e.g., metronomic temozolomide, cytoxan) or targeted therapies administered daily (e.g., gleevec, tarceva).
2. 4 weeks since last cytotoxic therapy.
3. 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen (e.g., carmustine).
8. Life expectancy ≥ 12 weeks.
9. KPS Score \> 60.
10. Adequate hepatic, renal, coagulation, and hematopoietic function:
1. Hemoglobin ≥ 8 g/dL.
2. Platelets ≥ 100,000/mm3.
3. Neutrophils ≥ 1,500/mm3.
4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN).
5. Urine protein creatinine (UPC) ratio \< 1 or urine dipstick for proteinuria ≤ 2+.
6. Alanine transaminase (ALT) \< 3 x ULN.
7. Aspartate transaminase (AST) \< 3 x ULN.
8. Prothrombin time ≤ 1.2 x ULN.
9. International Normalized Ratio (INR) \< 1.5.
10. Bilirubin \< 2 x ULN.
11. Center of region of interest (ROI) (i.e., tumor site) ≥30mm deep to skull bone.
12. If there is the potential for pregnancy, must agree to follow acceptable birth control methods to avoid conception.
13. Able and willing to have their hair shaved (either whole head or the region where the coupling membrane will touch) and placement of peripheral IV line prior to treatment.
Exclusion Criteria
2\) New York Heart Association (NYHA) Grade II or greater congestive heart failure requiring hospitalization within 12 months prior to screening.
3\) Hypertension (systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 100 mmHg).
4\) Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, severe cerebral or myocardial infarction, cardiac shunt, heart attack within the previous 12 months, stroke (except for transient ischemic attack; TIA) within the previous 6 months, or psychiatric illness/social situations that would limit compliance with study requirements.
5\) Unstable Pulmonary Disease or Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of screening.
6\) Implanted pacemaker, defibrillator or deep brain stimulator, or other implanted electronic devices in the brain or documented clinically significant arrhythmias.
7\) Major surgery such as intra-thoracic, intra-abdominal or intra-pelvic (with the exception of craniotomy), open biopsy or significant traumatic injury ≤ 4 weeks prior to screening, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device ≤ 1 week prior to screening, or who have not recovered from side effects of such procedure or injury.
8\) Known human immunodeficiency virus (HIV) positivity.
9\) Acute bacterial or fungal infection requiring intravenous antibiotics at the time of screening.
10\) Pregnant or breast-feeding women.
11\) Known sensitivity/allergy to MRI contrast agents, CT contrast agents, SonoVue® \[Lumason®\], bevacizumab, or any of their components.
12\) Abnormal baseline findings considered by the Investigator to indicate conditions that might affect study endpoints.
13\) Hemorrhage or cyst within the ROI.
14\) ROI in the deep center brain with crucial brain functions, such as in the region of the brain stem.
15\) The receipt of an investigational drug within a period of 4 weeks prior to the first FUS exposure.
16\) Use of any recreational drugs or a history of drug addiction.
17\) Difficulty lying supine and still for the FUS procedure length.
18\) Any other condition that, in the Investigator's judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NaviFUS Corporation
INDUSTRY
University of Cincinnati
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kyle Wang
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Kyle Wang, MD
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCCC-BN-24-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.